News

The pharmaceutical sector has gone on to face pressure as well as uncertainty in 2023, and that is in all likelihood going to continue in 2024, partially due to the execution as well as evolution of the Inflation Reduction...

It is worth noting that the biopharmaceutical sector has gone on to experience a revival when it comes to mergers and acquisitions in the second half of 2023. One can see three major reasons resulting in this uptick in...

The pharmaceutical backdrop is going through a remarkable shift pushed by disruptive technologies: Software as a Service- SaaS, Infrastructure as a Service- IaaS as well as Artificial Intelligence- AI. These technologies are revolutionizing pharma operations across the world. SaaS...

As per the results of a study done by GlobalData, the top issues when it comes to the pharmaceutical industry in 2024 are going to be inflation, geopolitical conflict, as well as drug pricing pressures. Data outcomes went on...

In a recent development, drugmakers such as Pfizer, Sanofi, as well as Takeda Pharmaceutical went on to plan to raise costs in the US when it comes to more than 500 drugs in early January 2024, according to data...

A paper that has been published in the European Journal of Pharmaceutics and Biopharmaceutics has gone on to review the present application status of Quality by Design- QbD within the framework of the ICH guidelines- ICH Q8(R2) – Q14...

The European Medicines Agency- EMA and the Heads of Medicines Agencies- HMAs have gone on to publish a plan that helps to set out a collaborative as well as coordinated strategy so as to maximize the advantages of artificial...